Please login to the form below

ipilimumab

This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.

GSK discontinues two feladilimab trials in head and neck cancer

An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been

Latest news

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

BMS’ checkpoint inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients.
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent.
BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS’ PD-L1 inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients. ... Armed with two Opdivo combinations in its arsenal, BMS is primed to take on
BMS aims for US approval of Opdivo combo in stomach cancer

inhibitor Yervoy (Ipilimumab).
BMS eyes approval for second Opdivo combo in kidney cancer

Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent.

More from news
Approximately 8 fully matching, plus 176 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth
Combined immunotherapies – potential and pitfalls

This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
Cancer immunotherapy: What's on the horizon?

drug Yervoy (ipilimumab) in an early-stage trial.
Pharma deals in February 2015

As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
Pharma deals during July 2014

Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

BMS appoints oncology development head

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
CytomX appoints Rachel Humphrey chief medical officer

drug Yervoy (ipilimumab).
Jonathan Dickinson joins Ariad from BMS

population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
Immunotherapy in oncology

This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary
ASCO 2015: What you missed in Chicago

In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Communications Career opportunity for Pharma professiona...: £30K to £40K

CEO, Head of Health, UK: Six figure salary

Omnichannel Strategy Consultant: Competitive Salary

Senior Account Manager: Competitive salary offered

Group Account Director, Medical/ Commercial launch, Healthcare c...: circa £90K

Medcomms Trainer, Medical Communications Agency, UK, Full or Par...: £50-75K

CEO Pricing & Market Access, UK: Six figure salary

PMHub

Add my company

Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship: The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation: world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass: 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....

Email:
Password:

Please login to the form below

ipilimumab

COVID-19 Updates and Daily News

Featured jobs

Quick links